Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment.

By Kallol Ray Chaudhuri, A. Schapira. Lancet Neurology, 2009

1,577 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/9d244898f5939d7d575fef1f8311cd79b76eb570

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Neurology

Citations in the corpus

Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease. (2019, background): “, 2018), alterations in neurotransmitter systems (Chaudhuri and Schapira, 2009; Delaville et al., 2011; Mayeux, 1990) and growth factors (O’Leary et al.”
The SH-SY5Y cell line in Parkinson’s disease research: a systematic review (2017, background): “PD presents with motor and non-motor symptoms [3, 4] that worsen with advancing age, leading to a need for assistance with all daily activities.”
Parkinson disease: from pathology to molecular disease mechanisms. (2013, background): “NMS create the biggest demand on clinical resources, they are poorly diagnosed and treated and they are the major determinant of disease outcome, increasing disability, poor quality of life, and entry into long-term care [13].”
Parkinson's disease symptoms: The patient's perspective (2010, background): “These symptoms consist of mood changes, cognitive decline, pain, sleep disturbance, and autonomic dysfunction.(1) Moreover, NMS have been reported to correlate with advancing age and severity of PD, although some of these symptoms such as depression, olfactory problems, constipation, and sleep disor”
Parkinson's disease: genetics and pathogenesis. (2011, background): “Motor features remain the essential criteria for clinical diagnosis of PD and are a major source of disability, but PD has a much broader impact on the nervous system (9, 10).”
A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics (2022, background): “Cell loss in different regions, including the nucleus basalis of Meynert, the raphe nuclei, the locus coeruleus, the pedunculopontine nucleus, the dorsal motor nucleus of the vagus nerve, the hypothalamus, and the olfactory bulb, account for the non-motor symptoms of PD [43].”